1. Home
  2. Policies
  3. Third party provider additional terms
  4. Liberum Capital Limited Research

Liberum Capital Limited Research

  1. You expressly agree and acknowledge that all proprietary rights in the research are the property of Liberum Capital Limited ("Liberum") and that the research is provided for information purposes only and should not be regarded as an offer or solicitation to buy or sell any security or other financial instrument. The research has no regard for the specific investment objectives, financial situation and needs of any specific person or entity. All expressions of opinions and estimates constitute a judgement and are those of the author and the research department of Liberum only and are subject to change without notice. The research is based on materials and sources that are believed to be reliable; however, they are not independently verified and are not guaranteed as being accurate. The research is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to therein. No representation or warranty either expressed or implied, is made nor responsibility of any kind is accepted by Liberum, its directors, officers, employees or agents either as to the accuracy or completeness of any information contained in this communication nor should it be relied on as such.
  2. You have no right or interest in the research except the rights to use it subject to the terms and conditions set out herein and in the research. The recipient acknowledges that the research requires a considerable amount of time, effort and money by Liberum. The recipient agrees that it will not remove any copyright notice disclosure, disclaimer or other notification or trade name or marks of Liberum that may appear in the research and that any permitted distribution of the research shall information as they appear in the research.
  3. Recipient shall comply with all applicable laws and regulations relating to use of the Research during the term of this Agreement.
  4. Please refer to www.liberumcapital.com for detailed disclosures relating to the research and Liberum.